724 resultados para Murat, Joaquin.
Resumo:
We consider exchange markets with heterogeneous indivisible goods. We are interested in exchange rules that are efficient and immune to manipulations via endowments (either with respect to hiding or destroying part of the endowment or transferring part of the endowment to another trader). We consider three manipulability axioms: hiding-proofness, destruction-proofness, and transfer-proofness. We prove that no rule satisfying efficiency and hiding-proofness (which implies individual rationality) exists. For two-agent exchange markets with separable and responsive preferences, we show that efficient, individually rational, and destruction-proof rules exist. However, for separable preferences, no rule satisfies efficiency, individual rationality, and destruction-proofness. In the case of transfer-proofness the compatibility with efficiency and individual rationality for the two-agent case extends to the unrestricted domain. For exchange markets with separable preferences and more than two agents no rule satisfies efficiency, individual rationality, and transfer-proofness.
Resumo:
The mutualistic symbiosis involving Glomeromycota, a distinctive phylum of early diverging Fungi, is widely hypothesized to have promoted the evolution of land plants during the middle Paleozoic. These arbuscular mycorrhizal fungi (AMF) perform vital functions in the phosphorus cycle that are fundamental to sustainable crop plant productivity. The unusual biological features of AMF have long fascinated evolutionary biologists. The coenocytic hyphae host a community of hundreds of nuclei and reproduce clonally through large multinucleated spores. It has been suggested that the AMF maintain a stable assemblage of several different genomes during the life cycle, but this genomic organization has been questioned. Here we introduce the 153-Mb haploid genome of Rhizophagus irregularis and its repertoire of 28,232 genes. The observed low level of genome polymorphism (0.43 SNP per kb) is not consistent with the occurrence of multiple, highly diverged genomes. The expansion of mating-related genes suggests the existence of cryptic sex-related processes. A comparison of gene categories confirms that R. irregularis is close to the Mucoromycotina. The AMF obligate biotrophy is not explained by genome erosion or any related loss of metabolic complexity in central metabolism, but is marked by a lack of genes encoding plant cell wall-degrading enzymes and of genes involved in toxin and thiamine synthesis. A battery of mycorrhiza-induced secreted proteins is expressed in symbiotic tissues. The present comprehensive repertoire of R. irregularis genes provides a basis for future research on symbiosis-related mechanisms in Glomeromycota.
Resumo:
Objectiu: valorar l'índex de recidiva simple o recidiva clínicament significativa dels diferents tipus de distròfies estromals anteriors en empelts corneals després cirurgia de queratoplàstia. Material i mètodes: S'ha realitzat una revisió retrospectiva del 1954 al 2008 al Centre d'Oftalmologia Barraquer, identificant a tots els pacients diagnosticats de distròfia corneal estromal anterior i de la membrana de Bowman (Distròfia de Reis Bücklers, Distròfia Granular, Distròfia reticular, distròfia macular) que han estat intervinguts de queratoplàstia penetrant (QP) o queratoplàstia laminar (QL). S'han utilitzat estadístics descriptius i la funció de supervivència amb les corbes de Kaplan Meier per dur a terme l'anàlisi de la mostra. Resultats: La mostra total del nostre estudi ha estat de 109 ulls de 66 pacients amb distròfies estromals anteriors operats de queratoplàstia: 8 casos de distròfies de la capa de Bowman (6 ulls amb CDRB o CDB-I (distròfia de Reis Bücklers), i 2 ulls amb CDTB o CDB-I (distròfia de Thiel Behnke)), 19 casos de distròfies granulars (CDG), 53 casos de distròfia de lattice (CDL) i 29 casos de distròfia macular (CDM). Amb un llarg de temps de seguiment (75-180 mesos de mitjana), la recurrència simple ha estat del 33% dels casos de CDRB amb 46 mesos de temps mitjà de supervivència, del 58, 8% dels casos de CDG amb 74.6 mesos de supervivència, el 41'5% de les CDL amb 106 mesos de supervivència i en el 10% dels casos amb CDM amb 96 mesos de temps mitjà de supervivència. La recurrència clínicament significativa es va manifestar en la seva majoria en els casos de CDL i CDG amb un temps mitjà de supervivència de 127.6 mesos i 124.1 mesos respectivament. El símptoma principal d'aquestes manifestacions clíniques va ser la disminució de la AV. Conclusió: La queratoplàstia penetrant és un tractament clàssic eficaç per als casos de distròfies estromals anteriors simptomàtics, amb opacitats profundes en l'estroma o fracàs previ d'altres teràpies menys invasives com la PTK. Com és d'esperar, per la seva origen genètic, l'aparició de recurrència de la distròfia després del trasplantament existeix i s'incrementa amb el major temps de seguiment. La tendència d'aquesta recidiva és a presentar inicialment en el pla cornial epitelial i requereix un llarg temps d'evolució per fer-se simptomàtica, especialment en els casos de CDG, CDL i CDM.
Resumo:
Objectiu: comparar la eficàcia entre Ranibizumab y Bevacizumab en el tractament de la DMAE de tipus exudatiu. Material i mètode Es tracta d’un estudi retrospectiu en el que es comparen a curt termini dos fàrmacs antiangiogènics utilitzats en el tractament de DMAE exudativa per via intravitrea: el Ranibizumab iel Bevacizumab. Hem seleccionat pacients amb DMAE exudativa tractats amb teràpia antiangiogènica i s’han distribuït en dos grups segons el tractament realitzat. Els pacients van ser tractats en el període comprés entre Gener del 2007 i Novembre del 2007, deprés d’uns mesos de l’aprovació del Ranibizumab intravitri per tractament de DMAE per la FDA. Resultats: La diferència entre l’AV mitja abans i després del tractament no era estadísticament significativa en cap dels dos grups tractats, mentre que la diferència entre el gruix macular antes i després del tractament en ambdós grups ha millorat de manera estadísticament significativa. Comparem a continuació el grau de millora per OCT en ambdós grups. Procedim a l’aplicació del test de Mann-Whitney per comparar si existeix diferència en la disminució del gruix de la màcula entre els dos grups. Evidenciem que la diferència no era clínicament significativa (p = 0.705) Conclusió: Els resultats obtinguts en el nostre estudi no mostren diferència entre els dos fàrmacs en el tractament de la DMAE exudativa a curt termini però reforcen la necessitat de futurs estudis prospectius i randomitzats
Resumo:
La distròfia endotelial de Fuchs es caracteritza per la formació de guttas endotelials i en estadis avançats pot induir edema corneal i pèrdua d’agudesa visual. A diferència del microscopi especular, el microscopi confocal té un disseny que permet evitar la llum aberrant causada per l’edema corneal o opacitats estromals. Comparant ambdues probes en la valoració de l’endoteli corneal en pacients amb distròfia de Fuchs, s’observa millor qualitat d’imatge per microscòpia confocal tot i que no es podia valorar la fiabilitat de l’esmentada proba en la determinació de la densitat cel•lular endotelial en les còrnies afectades.
Resumo:
La cirurgia refractiva és relativament nova i s’ha incrementat en les últimes dècades. La queratomileusis in situ és una de les tècniques refractives corneals més utilitzades actualment. L’astigmatisme és el defecte refractiu més freqüent i complex. Els resultats amb LASIK tòriques no són tant previsibles com en les esfèriques. La millora astigmàtica postoperatòria en aquells ulls amb astigmatisme (a favor, en contra i oblic) es manté molt estable en els controls successius (tant en miops com en hipermetrops). Existeix un descens important entre la mitjana en el preoperatori i les mitjanes dels controls successius en tots els tipus d’astigmatisme estudiats.
Resumo:
For patients with brain tumors identification of diagnostic and prognostic markers in easy accessible biological material, such as plasma or cerebrospinal fluid (CSF), would greatly facilitate patient management. MIC-1/GDF15 (growth differentiation factor 15) is a secreted protein of the TGF-beta superfamily and emerged as a candidate marker exhibiting increasing mRNA expression during malignant progression of glioma. Determination of MIC-1/GDF15 protein levels by ELISA in the CSF of a cohort of 94 patients with intracranial tumors including gliomas, meningioma and metastasis revealed significantly increased concentrations in glioblastoma patients (median, 229 pg/ml) when compared with control cohort of patients treated for non-neoplastic diseases (median below limit of detection of 156 pg/ml, p < 0.0001, Mann-Whitney test). However, plasma MIC-1/GDF15 levels were not elevated in the matching plasma samples from these patients. Most interestingly, patients with glioblastoma and increased CSF MIC-1/GDF15 had a shorter survival (p = 0.007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors.
Resumo:
Background With the emergence of influenza H1N1v the world is facing its first 21st century global pandemic. Severe Acute Respiratory Syndrome (SARS) and avian influenza H5N1 prompted development of pandemic preparedness plans. National systems of public health law are essential for public health stewardship and for the implementation of public health policy[1]. International coherence will contribute to effective regional and global responses. However little research has been undertaken on how law works as a tool for disease control in Europe. With co-funding from the European Union, we investigated the extent to which laws across Europe support or constrain pandemic preparedness planning, and whether national differences are likely to constrain control efforts. Methods We undertook a survey of national public health laws across 32 European states using a questionnaire designed around a disease scenario based on pandemic influenza. Questionnaire results were reviewed in workshops, analysing how differences between national laws might support or hinder regional responses to pandemic influenza. Respondents examined the impact of national laws on the movements of information, goods, services and people across borders in a time of pandemic, the capacity for surveillance, case detection, case management and community control, the deployment of strategies of prevention, containment, mitigation and recovery and the identification of commonalities and disconnects across states. Results Results of this study show differences across Europe in the extent to which national pandemic policy and pandemic plans have been integrated with public health laws. We found significant differences in legislation and in the legitimacy of strategic plans. States differ in the range and the nature of intervention measures authorized by law, the extent to which borders could be closed to movement of persons and goods during a pandemic, and access to healthcare of non-resident persons. Some states propose use of emergency powers that might potentially override human rights protections while other states propose to limit interventions to those authorized by public health laws. Conclusion These differences could create problems for European strategies if an evolving influenza pandemic results in more serious public health challenges or, indeed, if a novel disease other than influenza emerges with pandemic potential. There is insufficient understanding across Europe of the role and importance of law in pandemic planning. States need to build capacity in public health law to support disease prevention and control policies. Our research suggests that states would welcome further guidance from the EU on management of a pandemic, and guidance to assist in greater commonality of legal approaches across states.
Resumo:
BACKGROUND This study assesses the validity and reliability of the Spanish version of DN4 questionnaire as a tool for differential diagnosis of pain syndromes associated to a neuropathic (NP) or somatic component (non-neuropathic pain, NNP). METHODS A study was conducted consisting of two phases: cultural adaptation into the Spanish language by means of conceptual equivalence, including forward and backward translations in duplicate and cognitive debriefing, and testing of psychometric properties in patients with NP (peripheral, central and mixed) and NNP. The analysis of psychometric properties included reliability (internal consistency, inter-rater agreement and test-retest reliability) and validity (ROC curve analysis, agreement with the reference diagnosis and determination of sensitivity, specificity, and positive and negative predictive values in different subsamples according to type of NP). RESULTS A sample of 164 subjects (99 women, 60.4%; age: 60.4 +/- 16.0 years), 94 (57.3%) with NP (36 with peripheral, 32 with central, and 26 with mixed pain) and 70 with NNP was enrolled. The questionnaire was reliable [Cronbach's alpha coefficient: 0.71, inter-rater agreement coefficient: 0.80 (0.71-0.89), and test-retest intra-class correlation coefficient: 0.95 (0.92-0.97)] and valid for a cut-off value > or = 4 points, which was the best value to discriminate between NP and NNP subjects. DISCUSSION This study, representing the first validation of the DN4 questionnaire into another language different than the original, not only supported its high discriminatory value for identification of neuropathic pain, but also provided supplemental psychometric validation (i.e. test-retest reliability, influence of educational level and pain intensity) and showed its validity in mixed pain syndromes.
Resumo:
BACKGROUND Adherence to interferon β-1b (INFβ-1b) therapy is essential to maximize the beneficial effects of treatment in multiple sclerosis (MS). For that reason, the main objectives of this study are to assess adherence to INFβ-1b in patients suffering from MS in Spain, and to identify the factors responsible for adherence in routine clinical practice. METHODOLOGY/PRINCIPAL FINDINGS This was an observational, retrospective, cross-sectional study including 120 Spanish patients with MS under INFβ-1b treatment. Therapeutic adherence was assessed with Morisky-Green test and with the percentage of doses received. The proportion of adherent patients assessed by Morisky-Green test was 68.3%, being indicative of poor adherence. Nevertheless, the percentage of doses received, which was based on the number of injected medication, was 94.3%. The main reason for missing INFβ-1b injections was forgetting some of the administrations (64%). Therefore, interventions that diminish forgetfulness might have a positive effect in the proportion of adherent patients and in the percentage of doses received. In addition, age and comorbidities had a significant effect in the number of doses injected per month, and should be considered in the management of adherence in MS patients. CONCLUSION/SIGNIFICANCE Among all the available methods for assessing adherence, the overall consumption of the intended dose has to be considered when addressing adherence.
Resumo:
Studies on designed peptides that exhibit high tendencies for medium-induced conformational transitions have recently attracted much attention because structural changes are considered as molecular key processes in degenerative diseases. The experimental access to these events has been limited so far mainly due to the intrinsic tendency of the involved polypeptides for self-association and aggregation, e.g. amyloid P plaque formation, thought to be at the origin of Alzheimer's disease. We have developed a new concept termed 'switch-peptides' which allows the controlled onset of polypeptide folding and misfolding in vitro and in vivo, starting from a soluble, non-toxic precursor molecule. As a major feature, the folding process is initiated by enzyme-triggered N,O-acyl migrations restoring the native peptide backbone in situ. As the folding is set off in the moment of creating the bioactive molecule ('in statu nascendi', ISN), our concept allows for the first time the investigation of the early steps of protein misfolding as relevant in degenerative diseases, opening new perspectives for the rational design of therapeutically relevant compounds.
Resumo:
Gene expression-based prediction of genomic copy number aberrations in the chromosomal region 12q13 to 12q15 that is flanked by MDM2 and CDK4 identified Wnt inhibitory factor 1 (WIF1) as a candidate tumor suppressor gene in glioblastoma. WIF1 encodes a secreted Wnt antagonist and was strongly downregulated in most glioblastomas as compared with normal brain, implying deregulation of Wnt signaling, which is associated with cancer. WIF1 silencing was mediated by deletion (7/69, 10%) or epigenetic silencing by promoter hypermethylation (29/110, 26%). Co-amplification of MDM2 and CDK4 that is present in 10% of glioblastomas was associated in most cases with deletion of the whole genomic region enclosed, including the WIF1 locus. This interesting pathogenetic constellation targets the RB and p53 tumor suppressor pathways in tandem, while simultaneously activating oncogenic Wnt signaling. Ectopic expression of WIF1 in glioblastoma cell lines revealed a dose-dependent decrease of Wnt pathway activity. Furthermore, WIF1 expression inhibited cell proliferation in vitro, reduced anchorage-independent growth in soft agar, and completely abolished tumorigenicity in vivo. Interestingly, WIF1 overexpression in glioblastoma cells induced a senescence-like phenotype that was dose dependent. These results provide evidence that WIF1 has tumor suppressing properties. Downregulation of WIF1 in 75% of glioblastomas indicates frequent involvement of aberrant Wnt signaling and, hence, may render glioblastomas sensitive to inhibitors of Wnt signaling, potentially by diverting the tumor cells into a senescence-like state.
Resumo:
OBJETIVE: To report the data of the Home Parenteral Nutrition (HPN) registry of the NADYA-SENPE working group for the years 2011 and 2012. METHODOLOGY: We compiled the data from the on-line registry introduced by reviewers of NADYA group responsible for monitoring of NPD introduced by since January 1, 2011 to december 31, 2012. Included fields were: age, sex, diagnosis and reason for HPN, access path, complications, beginning and end dates, complementary oral or enteral nutrition, activity level, autonomy degree, product and fungible material supply, withdrawal reason and intestinal transplant indication. RESULTS: Year 2010: 184 patients from 29 hospitals , representing a rate of 3.98 patients/million inhabitants/ year 2011, with 186 episodes were recorded NPD . During 2012, 203 patients from 29 hospitals , representing a rate of 4.39 patients/million inhabitants/year 2012 , a total of 211 episodes were recorded NPD . CONCLUSIONS: We observe an increase in registered patients with respect to previous years.Neoplasia remains as the main pathology since 2003. Although NADYA is consolidated registry and has been indispensable source of information relevant to the understanding of the progress of Home Artificial Nutrition in our country, there is ample room for improvement. Especially that refers to the registration of pediatric patients and the registration of complications.
Resumo:
Ancien possesseur : Millin, Aubin-Louis (1759-1818)